Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ESTUDIOS


01 agosto 2017

JACC: CARDIOVASCULAR INTERVENTIONS. The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon

Marcus Thieme, Peter Von Bilderling, Christian Paetzel, Dimitrios Karnabatidis, Julio Perez Delgado, Michael Lichtenberg and Lutonix Global SFA Registry Investigators

Objectives: The Global SFA Registry sought to assess safety, clinical benefit, and outcomes of the Lutonix 035 drug-coated balloon (DCB) in a heterogeneous, real-world patient population at 12 and 24 months.

01 agosto 2017

JACC: CARDIOVASCULAR INTERVENTIONS. Self-Expanding Versus Balloon-Expandable Stents for Iliac Artery Occlusive Disease: The Randomized ICE Trial

Hans Krankenberg, Thomas Zeller, Maja Ingwersen, Josefin Schmalstieg, Hans Martin Gissler, Sigrid Nikol, Iris Baumgartner, Nicolas Diehm, Estell Nickling, Stefan Müller-Hülsbeck, Rainer Schmiedel, Giovanni Torsello, Willibald Hochholzer, Christian Stelzner, Klaus Brechtel, Wulf Ito, Ralph Kickuth, Erwin Blessing, Marcus Thieme, Jaroslaw Nakonieczny, Thomas Nolte, Ragnar Gareis, Harald Boden and Sebastian Sixt

Objectives: Atherosclerosis of iliac arteries is widespread. As inflow vessels, they are of great clinical significance and increasingly being treated by endovascular means. Most commonly, stents are implanted.

01 junio 2017

JACC: CARDIOVASCULAR INTERVENTIONS. The Effect of Clinical Care Location on Clinical Outcomes After Peripheral Vascular Intervention in Medicare Beneficiaries

Ryan S. Turley, Xiaojuan Mi, Laura G. Qualls, Sreekanth Vemulapalli, Eric D. Peterson, Manesh R. Patel, Lesley H. Curtis and W. Schuyler Jones

Objectives: Modifications in reimbursement rates by Medicare in 2008 have led to peripheral vascular interventions (PVI) being performed more commonly in outpatient and office-based clinics. The objective of this study was to determine the effects of this shift in clinical care setting on clinical outcomes after PVI.

01 junio 2017

JACC: CARDIOVASCULAR INTERVENTIONS. The Use of Embolic Protection Devices Is Associated With a Lower Stroke and Death Rate After Carotid Stenting

Christoph Knappich, Andreas Kuehnl, Pavlos Tsantilas, Sofie Schmid, Thorben Breitkreuz, Michael Kallmayer, Alexander Zimmermann and Hans-Henning Eckstein

Objectives: The aim of this study was to analyze the association between intraprocedural and periprocedural variables and in-hospital stroke or death rate after carotid artery stenting.

01 julio 2017

JACC: CARDIOVASCULAR INTERVENTIONS. Stenting or Surgery for De Novo Common Femoral Artery Stenosis

Yann Gouëffic, Nellie Della Schiava, Fabien Thaveau, Eugenio Rosset, Jean-Pierre Favre, Lucie Salomon du Mont, Jean-Marc Alsac, Réda Hassen-Khodja, Thierry Reix, Eric Allaire, Eric Ducasse, Raphael Soler, Béatrice Guyomarc’h and Bahaa Nasr

Objectives: The TECCO (Traitement des Lésions Athéromateuses de l’Artère Fémorale Commune par Technique Endovasculaire Versus Chirurgie Ouverte [Endovascular Versus Open Repair of the Common Femoral Artery]) trial is a randomized comparison of safety and efficacy of stenting versus open surgery for de novo common femoral artery (CFA) stenosis.

01 diciembre 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy

Meritxell Mellado, José I. Pijoan, David Jiménez, Alfonso Muriel, Drahomir Aujesky, Laurent Bertoletti, Herve Decousus, Deisy Barrios, Albert Clará, Roger D. Yusen, Manuel Monreal and RIETE Investigators

Objectives: The aim of this study was to assess the effectiveness of inferior vena cava (IVC) filter use among patients who develop recurrent symptomatic venous thromboembolism (VTE) on anticoagulant therapy.

01 diciembre 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Endovascular Therapy Versus Bypass Surgery as First-Line Treatment Strategies for Critical Limb Ischemia

Theodosios Bisdas, Matthias Borowski, Konstantinos Stavroulakis, Giovanni Torsello, CRITISCH Collaborators, Farzin Adili, Kai Balzer, Arend Billing, Dittmar Böckler, Daniel Brixner, Sebastian E. Debus, Hans-Henning Eckstein, Hans-Joachim Florek, Asimakis Gkremoutis, Reinhardt Grundmann, Thomas Hupp, Tobias Keck, Joachim Gerß, Wojciech Klonek, Werner Lang, Björn May, Alexander Meyer, Bernhard Mühling, Alexander Oberhuber, Holger Reinecke, Christian Reinhold, Ralf-Gerhard Ritter, Hubert Schelzig, Christian Schlensack, Thomas Schmitz-Rixen, Karl-Ludwig Schulte, Matthias Spohn, Markus Steinbauer, Martin Storck, Matthias Trede, Christian Uhl, Barbara Weis-Müller, Heiner Wenk, Thomas Zeller, Sven Zhorzel and Alexander Zimmermann

Objectives: The most effective first-line treatment between endovascular therapy and bypass surgery for patients with critical limb ischemia (CLI) is still not well defined. The primary aim of the interim analysis of CRITISCH (Registry of First-Line Treatments in Patients With Critical Limb Ischemia) was to compare both treatment options in a prospective confirmatory manner.

01 noviembre 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Comparative Assessment of Procedure Cost and Outcomes Between Guidewire and Crossing Device Strategies to Cross Peripheral Artery Chronic Total Occlusions

Subhash Banerjee, Haekyung Jeon-Slaughter, Shirling Tsai, Atif Mohammad, Mazin Foteh, Mazen Abu-Fadel, Osvaldo S. Gigliotti, Ian Cawich, Gerardo Rodriguez, Dharam Kumbhani, Tayo Addo, Michael Luna, Tony S. Das, Anand Prasad, Ehrin J. Armstrong, Nicolas W. Shammas and Emmanouil S. Brilakis

Objectives: The aim of this study was to assess actual procedural costs and outcomes comparing wire-catheter and dedicated chronic total occlusion (CTO) device strategies to cross peripheral artery CTOs.

01 octubre 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P–TIMI 50 Trial

Marc P. Bonaca, Mark A. Creager, Jeffrey Olin, Benjamin M. Scirica, Ian C. Gilchrist Jr., Sabina A. Murphy, Erica L. Goodrich, Eugene Braunwald and David A. Morrow

Objectives: The aim of this study was to determine whether the reduction in peripheral revascularization with vorapaxar in patients with peripheral artery disease (PAD) is directionally consistent across indications, including acute limb ischemia, progressively disabling symptoms, or both.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.